₹1799
Overview of Ajanta Pharma Ltd
Ajanta Pharma is one of the 33 stocks that have given 100% returns in the last 20 years and can be termed through-the-cycle (TTC) compounders 100-baggers.
Ajanta Pharma Leads in Sales Growth - 18 Sep, 2023
Ajanta Pharma Ltd emerged as the leader in terms of growth in August with sales growth of 11.6 percent on year.
Ajanta Pharma Hits Record High on Strong Business Outlook - 13 Sep, 2023
Ajanta Pharma's stock rallies 11% to a record high on improved business outlook and strong Q1-FY24 results. The company also outperformed the market with its ophthalmology, pain therapy, and dermatology therapies.
Ajanta Pharma Receives USFDA Approval - 31 Aug, 2023
Ajanta Pharma Ltd has received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200mg. The company can launch Topiramate on February 1, 2026 or earlier under certain circumstances.
Ajanta Pharma Receives USFDA Approval for Topiramate Extended-Release Capsules - 30 Aug, 2023
Ajanta Pharma has received final approval from the USFDA to market Topiramate Extended-Release Capsules, a generic version of Trokendi XR™. The drug can be launched on February 1, 2026, or earlier under certain circumstances.
Ajanta Pharma's Debt Management Analyzed - 26 Aug, 2023
An article analyzes Ajanta Pharma Limited's use of debt, focusing on its balance sheet and ability to manage its debt safely.
Ajanta Pharma Preferred by Brokerage Despite Decent US Approval - 24 Aug, 2023
Brokerage reports that Ajanta Pharma has a decent approval in the last few months, supporting their US growth quarter-on-quarter. The brokerage continues to prefer Ajanta Pharma.
Ajanta Pharma Hits New 52-Week High - 17 Aug, 2023
Ajanta Pharma Ltd's stock hits a new 52-week high at Rs 1,804.70 due to the company's focus on pharmaceutical research and development in the healthcare sector.
Ajanta Pharma Hits 52-Week High - 16 Aug, 2023
Ajanta Pharma Ltd's stock hits a new milestone by reaching a 52-week high of Rs 1,804.00.
Ajanta Pharma Registers Growth in Indian Market - 14 Aug, 2023
Ajanta Pharma Ltd has registered growth in the 8-11% YoY range in the Indian pharma market for July.
Ajanta Pharma Hits All-Time Highs - 08 Aug, 2023
Ajanta Pharma's stock is trading at all-time highs, with shares above its IPO price. The stock also exhibits strong buying activity, but investors should watch for potential trend reversals.
Ajanta Pharma Announces Dividend; RSI Indicates Overbought Situation - 04 Aug, 2023
Ajanta Pharma Ltd announces an interim dividend of Rs 10 per equity share and a special dividend of Rs 15. The company's RSI has surpassed 80, indicating a potential overbought situation.
Ajanta Pharma Stock Reaches 52-Week High - 03 Aug, 2023
Ajanta Pharma Ltd's stock reached a 52-week high of Rs 1,776.70.
Ajanta Pharma Q1FY24 Results Show Improvement in Margins - 01 Aug, 2023
Ajanta Pharma's Q1FY24 results show improvement in gross and EBITDA margins due to softening of raw material and freight costs. Management maintains double-digit revenue growth and margin guidance for FY24. ICICI Securities raises earnings estimates by 7%/6% and maintains BUY call with target price of INR 1,870.
Ajanta Pharma Posts In-Line Sales with Better-Than-Expected Profitability - 31 Jul, 2023
Ajanta Pharma's 1QFY24 sales were in line with expectations, but profitability exceeded estimates due to lower raw material and freight costs. Earnings estimates for FY24/FY25 have been raised by 7.5% each, and the stock is rated a BUY with a TP of INR1,800.
Ajanta Pharma Stock Breaks Out Above Previous Swing High - 30 Jul, 2023
Ajanta Pharma Ltd's stock has broken out above its previous swing high and is set to target even higher levels in the coming months, with a potential target of around 2200. The company is also trading ex-dividend with an upcoming dividend of ₹25.00 per share.
Ajanta Pharma Reports Strong Q1FY24 Results - 28 Jul, 2023
Ajanta Pharma Ltd.'s Q1FY24 net profit surged 19.2% YoY to Rs. 208.1 crore, revenue grew 7.4% YoY to Rs. 1021 crore. The company announced a special dividend of Rs. 15 per share and regular dividend of Rs. 10 per share.
Ajanta Pharma Reports Strong Q1 Results and Approves Dividend - 27 Jul, 2023
Ajanta Pharma Ltd reported strong Q1 results with revenue at Rs. 1,021 crore and approved a 1st interim dividend of Rs. 315 cr for FY 2024.
Ajanta Pharma Hits 52-Week High - 25 Jul, 2023
Ajanta Pharma's stock soared to a new high, reaching Rs 1,568.00 due to its strong presence in domestic and international markets.
Ajanta Pharma Board to Consider Interim Dividend and Q1 Results - 24 Jul, 2023
Ajanta Pharma's board of directors will meet on July 27 to consider declaring an interim dividend, if any, for the financial year ending March 31, 2024. The company will also announce its unaudited financial results for the June quarter in the same meeting.
Source: S&P Global Market Intelligence
0.11%
Downside
Day's Volatility:0.33%
Upside
0.22%
38.21%
Downside
52 Weeks Volatility:44.07%
Upside
5.86%
Returns % | |
1 Month Return | 4.67 % |
3 Month Return | 22.03 % |
1 Year Return | 39.86 % |
Market Stats | |
Previous Close | ₹1,799.90 |
Open | ₹1,803.00 |
Volume | 3.81L |
Market Cap | ₹23,061.43Cr |
Organisation | Ajanta Pharma Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Fundamentals of Ajanta Pharma Ltd
Retail Investor have increased holdings from 7.74% to 7.78% in Jun 2023 quarter
Foreign Institutions have increased holdings from 10.03% to 10.19% in Jun 2023 quarter
In the last 1 year, AJANTPHARM has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
In the last 3 years, AJANTPHARM stock has moved up by 68.6%
Promoters holdings remained unchanged at 66.21% of holdings in Jun 2023 quarter
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 121.5% return, outperforming this stock by 52.9%
Netprofit is down for the last 4 quarters, 174.62 Cr → 122.25 Cr (in ₹), with an average decrease of 11.2% per quarter
Mutual Funds have decreased holdings from 13.72% to 13.07% in Jun 2023 quarter
Revenue is down for the last 2 quarters, 1.00K Cr → 918.67 Cr (in ₹), with an average decrease of 8.7% per quarter
Ajanta Pharma Ltd in the last 5 years
Lowest (17.12x)
June 6, 2018
Today (36.89x)
September 29, 2023
Industry (48.71x)
September 29, 2023
Highest (37.33x)
September 13, 2023
Funds | Holdings |
![]() | 1.58% |
![]() | 0.97% |
![]() | 3.02% |
![]() | 1.09% |
![]() | 1.52% |
Investors | Holdings % | Prev. 3 periods | 3M change |
---|---|---|---|
Promoter Holdings | 66.21% | 0.00 | |
Foreign Institutions | 10.19% | 1.62 | |
Mutual Funds | 13.07% | ||
Retail Investors | 7.78% | 0.62 | |
Others | 2.74% | 18.96 |
Technicals of Ajanta Pharma Ltd share
News & Events of Ajanta Pharma Ltd
Ajanta Pharma Ltd(AJANTPHARM | Price |
---|---|
52 Week High | ₹1904.45 |
52 Week Low | ₹1111.6 |
Ajanta Pharma Ltd(AJANTPHARM | Returns |
---|---|
1 Day Returns | -0.9% |
1 Month Returns | 4.67% |
3 Month Returns | 22.03% |
1 Year Returns | 39.86% |